A phase II study of S-1 and oxaliplatin as first-line therapy for patients with recurrent or metastatic gastric cancer

被引：0
|
作者：
Kim, H.
Lee, G.
Kim, H.
Lee, O.
Hwang, I.
Kang, J.
机构：
[1] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea
[2] Kangwon Natl Univ, Sch Med, Chunchon, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.15583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15583
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A dose-escalation study of docetaxel, oxaliplatin and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
    Sato, Yasushi
    Sagawa, Tamotsu
    Takahashi, Yasuo
    Ohnuma, Hiroyuki
    Hamaguchi, Kyoko
    Hirakawa, Masahiro
    Fujikawa, Koshi
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [22] S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study
    Lu, Yiming
    Liu, Zanchao
    Zhang, Jun
    JOURNAL OF CHEMOTHERAPY, 2014, 26 (03) : 159 - 164
  • [23] Retrospective comparative analysis of S-1 and oxaliplatin or cisplatin as first-line therapy in metastatic gastric cancer in a European population
    Koumarianou, A.
    Ntavatzikos, A.
    Vallilas, C.
    Kampoli, K.
    Kokosaiou, Z.
    Karamouzis, M. V.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S914
  • [24] S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
    Kim, S. Y.
    Hong, Y. S.
    Shim, E. K.
    Kong, S-Y
    Shin, A.
    Baek, J. Y.
    Jung, K. H.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1420 - 1427
  • [25] S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
    S Y Kim
    Y S Hong
    E K Shim
    S-Y Kong
    A Shin
    J Y Baek
    K H Jung
    British Journal of Cancer, 2013, 109 : 1420 - 1427
  • [26] A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer
    Jae Jin Lee
    Si-Young Kim
    Hyun-Cheol Chung
    Kyung-Hee Lee
    Hong-Suk Song
    Won-Ki Kang
    Young-Seon Hong
    In-Sil Choi
    Young Yeul Lee
    In-Sook Woo
    Jin-Hyuk Choi
    Cancer Chemotherapy and Pharmacology, 2009, 63
  • [27] A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer
    Lee, Jae Jin
    Kim, Si-Young
    Chung, Hyun-Cheol
    Lee, Kyung-Hee
    Song, Hong-Suk
    Kang, Won-Ki
    Hong, Young-Seon
    Choi, In-Sil
    Lee, Young Yeul
    Woo, In-Sook
    Choi, Jin-Hyuk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1083 - 1090
  • [28] Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer
    Yamada, Yasuhide
    Yamaguchi, Tatsuro
    Matsumoto, Hiroshi
    Ichikawa, Yasushi
    Goto, Ayumu
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1690 - 1696
  • [29] Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer
    Yasuhide Yamada
    Tatsuro Yamaguchi
    Hiroshi Matsumoto
    Yasushi Ichikawa
    Ayumu Goto
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhiro Shimada
    Investigational New Drugs, 2012, 30 : 1690 - 1696
  • [30] Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma
    Sun, Si
    Yu, Hui
    Wang, Huijie
    Zhang, Hai
    Wu, Xianghua
    Wang, Jialei
    Chang, Jianhua
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 115 - 122
12345